Abstract Number: PB1415
Meeting: ISTH 2020 Congress
Background: Sulodexide is a mammalian tissue derived glycosaminoglycan antithrombotic agent which is clinically used for the management of vascular disorders and is pharmacologically active after both parenteral and oral administration.
Aims: The purpose of this study is to compare the relative effect of sulodexide in mediating heparin induced thrombocytopenia (HIT) antibodies induced aggregation of human platelets in a standardized test system which is developed to compare the effects of heparins and related drugs.
Methods: Active pharmaceutical ingredients (API versions of sulodexide), fast moving heparin and dermatan sulfate were obtained from Alfa Sigma (Bologna, Italy). API versions of UFH were obtained from Medefil, Inc (Glendale Heights, IL, USA). The source of functional HIT antibody represented a frozen pool of aphresis fluid (AF) collected from five clinically confirmed heparin induced thrombocytopenia patients. All results were compiled in terms of percent aggregation of platelets and represented as mean + standard deviation.
Results: UFH produced a concentration dependent aggregation from 0 – 10 ug/ml reaching a peak aggregation of 60 + 18.76%. Sulodexide produced a relatively weaker aggregatory response and produced mild aggregation in the same concentration range exhibiting comparable platelet aggregation at 10 ug/ml. The fast moving heparin component of sulodexide produced a concentration dependent response comparable to heparin reaching a maximum aggregation of 66 + 30.67% at 10 ug/ml. The dermatan sulfate component did not produce any significant aggregation of platelets and no concentration dependence was observed (< 10% aggregation).
Conclusions: These results clearly show that in comparison to heparin, sulodexide produces a relatively weaker response in the functional HIT antibody screening studies. However, the fast moving heparin component of sulodexide produces comparable responses to UFH whereas dermatan sulfate has much weaker aggregation response.
To cite this abstract in AMA style:Farooqui A, Hoppensteadt D, Iqbal O, Bacher C, Lewis M, Walenga J, Kouta A, Jeske W, Lewis B, Fareed J. Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies as Investigated in Platelet Aggregation Assays [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/interaction-of-unfractionated-heparin-and-sulodexide-with-functional-anti-heparin-platelet-factor-4-antibodies-as-investigated-in-platelet-aggregation-assays/. Accessed January 28, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/interaction-of-unfractionated-heparin-and-sulodexide-with-functional-anti-heparin-platelet-factor-4-antibodies-as-investigated-in-platelet-aggregation-assays/